Global News

Basilea awarded $100M BARDA contract for ceftobiprole program

Thursday, April 21, 2016

Basilea Pharmaceutica has announced that the Biomedical Advanced Research and Development Authority (BARDA), a division within the U.S. Department of Health and Human Services` Office of the Assistant Secretary for Preparedness and Response, has entered into a contract with Basilea Pharmaceutica International for the clinical phase III development aiming at regulatory approval of Basilea`s broad-spectrum antibiotic ceftobiprole in the U.S.

[Read More]

DNAnexus, Solvebio partner to make genomic data more actionable

Thursday, April 21, 2016

DNAnexus, a cloud-based genome informatics and data management provider, has announced a partnership with SolveBio, a global provider of Genomics Intelligence, to integrate the two platforms and provide seamless access to SolveBio’s curated data and analysis services. Researchers globally will have the ability to move quickly from genomic data analysis to interpretation, freeing up time to focus on generating uniquely actionable biological insights.

[Read More]

Medrio, Clinartis partner

Thursday, April 21, 2016

Medrio, a Software as a Service (SaaS) company providing cloud-based data management capabilities to clinical researchers, and Clinartis, a CRO providing clinical trial services in the U.S. and Europe, have announced a new partnership under Medrio’s Partner Program. Clinartis and Medrio have cultivated a business relationship through numerous phase I studies for which the CRO has utilized Medrio’s flagship phase I-focused product, m1.

[Read More]

CRF Health selected to support COPD trials involving 19,000+ patients

Wednesday, April 20, 2016

CRF Health, a global provider of eCOA solutions for the life sciences industry, has announced that its TrialMax platform has been adopted by a developer of therapeutics for respiratory disease conditions to support one of the largest recorded phase III studies into chronic obstructive pulmonary disease (COPD). The trial, involving more than 19,000 patients, will use the TrialMax platform to deliver electronic versions of key COPD instruments, enabling investigators to monitor exacerbations, while making compliance as easy as possible for patients.

[Read More]